

2015

# Diagnostic ultrasound estimates of muscle mass and muscle quality discriminate between women with and without sarcopenia

Catheeja Ismail

Johannah Zabal

Haniel J. Hernandez

Paula Woletz

Heather Manning

*See next page for additional authors*

Follow this and additional works at: [https://hsrc.himmelfarb.gwu.edu/smhs\\_medicine\\_facpubs](https://hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs)



Part of the [Medicine and Health Sciences Commons](#)

---

## Recommended Citation

Ismail C, Zabal J, Hernandez HJ, Woletz P, Manning H, Teixeira C, DiPietro L, Blackman MR and Harris-Love M (2015). Diagnostic ultrasound estimates of muscle mass and muscle quality discriminate between women with and without sarcopenia. *Front. Physiol.* 6:302. doi: 10.3389/fphys.2015.00302

This Journal Article is brought to you for free and open access by the Medicine at Health Sciences Research Commons. It has been accepted for inclusion in Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact [hsrc@gwu.edu](mailto:hsrc@gwu.edu).

---

**Authors**

Catheeja Ismail, Johannah Zabal, Haniel J. Hernandez, Paula Woletz, Heather Manning, Carla Teixeira, Loretta DiPietro, Marc R. Blackman, and Michael O. Harris-Love

## Diagnostic ultrasound estimates of muscle mass and muscle quality discriminate between women with and without sarcopenia

Catheeja Ismail<sup>1, 2</sup>, Johannah Zabal<sup>3, 4</sup>, Haniel J. Hernandez<sup>1, 5</sup>, Paula Woletz<sup>1</sup>, Heather Manning<sup>6</sup>, Carla Teixeira<sup>1, 7</sup>, Loretta DiPietro<sup>6</sup>, Marc R. Blackman<sup>8, 2, 9, 10, 11</sup>, Michael Harris-Love<sup>1, 8, 6\*</sup>

<sup>1</sup>Clinical Research Center - Human Performance Research Unit, Washington DC VA Medical Center, USA, <sup>2</sup>Department of Medicine, The George Washington University, USA, <sup>3</sup>Department of Health Sciences, Marymount University, USA, <sup>4</sup>Department of Physical Therapy & Health Care Sciences, George Washington University, USA, <sup>5</sup>Physical Medicine & Rehabilitation Service, Washington DC VA Medical Center, USA, <sup>6</sup>Department of Exercise and Nutritional Sciences, George Washington University, USA, <sup>7</sup>The Department of Biological Sciences, Columbia College, USA, <sup>8</sup>Research Service, Veterans Affairs Medical Center, USA, <sup>9</sup>Departments of Biochemistry and Molecular Medicine, The George Washington University, USA, <sup>10</sup>Departments of Medicine and Rehabilitation Medicine, Georgetown University School of Medicine, USA, <sup>11</sup>The Johns Hopkins University School of Medicine, Johns Hopkins University, USA

**Submitted to Journal:**

Frontiers in Physiology

**Specialty Section:**

Striated Muscle Physiology

**ISSN:**

1664-042X

**Article type:**

Original Research Article

**Received on:**

10 Sep 2015

**Accepted on:**

12 Oct 2015

**Provisional PDF published on:**

12 Oct 2015

**Frontiers website link:**

[www.frontiersin.org](http://www.frontiersin.org)

**Citation:**

Ismail C, Zabal J, Hernandez HJ, Woletz P, Manning H, Teixeira C, Dipietro L, Blackman MR and Harris-love M(2015) Diagnostic ultrasound estimates of muscle mass and muscle quality discriminate between women with and without sarcopenia. *Front. Physiol.* 6:302. doi:10.3389/fphys.2015.00302

**Copyright statement:**

© 2015 Ismail, Zabal, Hernandez, Woletz, Manning, Teixeira, Dipietro, Blackman and Harris-love. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](http://creativecommons.org/licenses/by/4.0/). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

This Provisional PDF corresponds to the article as it appeared upon acceptance, after peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon.

Provisional

# Diagnostic ultrasound estimates of muscle mass and muscle quality discriminate between women with and without sarcopenia

Catheeja Ismail, RDMS, EdD<sup>1,2</sup>; Johannah Zabal, BS, MS<sup>3,4</sup>; Haniel J. Hernandez, PT, DPT<sup>1,5</sup>; Paula Woletz, MPH, RDMS, RDCS<sup>1</sup>; Heather Manning, MS<sup>6</sup>; Carla Teixeira, BS<sup>1,7</sup>; Loretta DiPietro, PhD, MPH<sup>6</sup>; Marc R. Blackman, MD<sup>2,9-11</sup>; Michael O. Harris-Love, PT, DSc, MPT<sup>1,6,8\*</sup>

<sup>1</sup> Muscle Morphology, Mechanics and Performance Laboratory, Clinical Research Center - Human Performance Research Unit, Veterans Affairs Medical Center, Washington DC, USA

<sup>2</sup> Department of Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA

<sup>3</sup> Department of Physical Therapy & Health Care Sciences, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA

<sup>4</sup> Department of Health Sciences, Malek School of Health Professions, Marymount University, Arlington, VA, USA

<sup>5</sup> Physical Medicine & Rehabilitation Service, Veterans Affairs Medical Center, Washington DC, USA

<sup>6</sup> Department of Exercise and Nutritional Sciences, Milken Institute School of Public Health, The George Washington University, Washington DC, USA

<sup>7</sup> The School of Kinesiology and Health Studies, Queen's University, Kingston, ON Canada

<sup>8</sup> Research Service, Veterans Affairs Medical Center, Washington DC, USA

<sup>9</sup> Departments of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington DC, USA

<sup>10</sup> Departments of Medicine and Rehabilitation Medicine, Georgetown University School of Medicine, Washington DC, USA

<sup>11</sup> The Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, MD, USA

**\*Correspondence:** Dr. Michael O. Harris-Love, Muscle Morphology, Mechanics and Performance Laboratory, Clinical Research Center - Human Performance Research Unit, Veterans Affairs Medical Center, 50 Irving St NW, 11G, Washington, DC 20422, USA.

[michael.harris-love@va.gov](mailto:michael.harris-love@va.gov) (ResearcherID/ORCID: 0000-0002-1842-3269)

**Keywords:** sarcopenia, diagnostic ultrasound, geriatric assessment, body composition, dual-energy X-ray absorptiometry, muscle performance, muscle strength, myosteatosis

42

43

44 **Short running title:** Ultrasound muscle characteristics in women

45

46 **Manuscript Category:** Original Research (*Frontiers in Physiology – Striated Muscle Physiology*)

47

48

49

Provisional

50

51 **Abstract**

52 **Introduction:** Age-related changes in muscle mass and muscle tissue composition contribute to  
53 diminished strength in older adults. The objectives of this study are to examine if an assessment  
54 method using mobile diagnostic ultrasound augments well-known determinants of lean body mass  
55 (LBM) to aid sarcopenia staging, and if a sonographic measure of muscle quality is associated with  
56 muscle performance.

57 **Methods:** Twenty community-dwelling female subjects participated in the study (age =  $43.4 \pm 20.9$   
58 years; BMI: 23.8, interquartile range: 8.5). Dual energy X-ray absorptiometry (DXA) and diagnostic  
59 ultrasound morphometry were used to estimate LBM. Muscle tissue quality was estimated via the  
60 echogenicity using grayscale histogram analysis. Peak force was measured with grip dynamometry  
61 and scaled for body size. Bivariate and multiple regression analyses were used to determine the  
62 association of the predictor variables with appendicular lean mass ( $aLM/ht^2$ ), and examine the  
63 relationship between scaled peak force values and muscle echogenicity. The sarcopenia LBM cut  
64 point value of  $6.75 \text{ kg/m}^2$  determined participant assignment into the Normal LBM and Low LBM  
65 subgroups.

66 **Results:** The selected LBM predictor variables were body mass index (BMI), ultrasound  
67 morphometry, and age. Although BMI exhibited a significant positive relationship with  $aLM/ht^2$  (adj.  
68  $R^2 = .61$ ,  $p < .001$ ), the strength of association improved with the addition of ultrasound morphometry  
69 and age as predictor variables (adj.  $R^2 = .85$ ,  $p < .001$ ). Scaled peak force was associated with age and  
70 echogenicity (adj.  $R^2 = .53$ ,  $p < .001$ ), but not LBM. The Low LBM subgroup of women ( $n = 10$ ) had  
71 higher scaled peak force, lower BMI, and lower echogenicity values in comparison to the Normal  
72 LBM subgroup ( $n = 10$ ;  $p < .05$ ).

73 **Conclusions:** Diagnostic ultrasound morphometry values are associated with LBM, and improve the  
74 BMI predictive model for  $aLM/ht^2$  in women. In addition, ultrasound proxy measures of muscle  
75 quality are more strongly associated with strength than muscle mass within the study sample.

76

## 77 Introduction

78

79 Age-related declines in strength typically begin during the 4th decade of life, and range from .6% to  
80 1.3% per year in people over 65 years of age (1–3). Sarcopenia, an age-related loss of muscle mass  
81 that contributes to diminished muscle power and independent mobility, has been noted as a  
82 significant cause of morbidity in older adults (4,5). The pathogenesis of sarcopenia is multifactorial  
83 and likely involves inflammatory, endocrine, neurological, and behavioral contributors. Importantly,  
84 the strength changes in older adults are often accompanied by myosteatosis, an increase in  
85 intramuscular adipose and connective tissue, along with the concomitant decrease in skeletal muscle  
86 cross-sectional area (1,6). These changes in *muscle quality* (e.g., muscle tissue composition,  
87 metabolic efficiency, or altered mechanics) may negatively impact functional performance in both  
88 women and men. Moreover, increased myosteatosis has been shown to be associated with decreased  
89 bone mineral density and lean body mass (LBM) in older women (7).

90

91 Diminished LBM, muscle tissue composition, and muscle performance, are significant contributors  
92 to geriatric syndromes such as sarcopenia and frailty, and merit focused attention regarding  
93 standardized assessment and rehabilitation intervention strategies. Despite the substantial clinical and  
94 financial burden attributed to sarcopenia, it remains an under-diagnosed condition that is rarely  
95 subject to a systematic screening process for older adults (8). The most commonly used LBM  
96 criterion for sarcopenia staging is appendicular lean mass (aLM, also expressed as aLM/ht<sup>2</sup>), as  
97 measured by dual energy X-ray absorptiometry (DXA) (9,10). However, due to space requirements  
98 for DXA, initial equipment costs, body size constraints, and general barriers related to specialized  
99 LBM assessment software and examiner training, DXA assessment of aLM is not an ideal measure  
100 for large scale sarcopenia clinical trials, bedside assessment, or community health screening efforts.  
101 Individual attributes such as age and sex are meaningful determinants of LBM, and alternative  
102 anthropometric methods have been used to estimate LBM (11). In addition, BMI has been shown to  
103 explain a significant proportion of the variance in LBM values (12). However, these alternative  
104 estimates of LBM have limited utility as proxy measures, and the standard DXA examination does  
105 not provide information concerning muscle quality.

106

107 The use of diagnostic ultrasound for body composition assessment has been explored in concurrent  
108 validity studies involving DXA, hydrostatic weighing, and computed tomography (CT) imaging  
109 (13,14). Also, sonographic characteristics of skeletal muscle have been associated with density values  
110 from magnetic resonance imaging (MRI) (15) and hydrodensitometry (16) in Japanese adults. Unlike  
111 DXA, but similar to magnetic resonance and CT imaging, diagnostic ultrasound may be used to  
112 assess muscle quality via tissue characteristics. Muscle quality may be assessed via diagnostic  
113 ultrasound due to the hyperechoic nature of the non-contractile tissue associated with myosteatosis  
114 (17). The use of diagnostic ultrasound for muscle tissue characterization has also been successful in  
115 the detection of various disorders such as Duchenne muscular dystrophy (18–21). Moreover, the  
116 analysis of muscle tissue acquired via biopsy suggests that echogenicity is more strongly associated  
117 with intramuscular adipose tissue rather than fibrosis (22). Consequently, diagnostic ultrasound may  
118 be a practical alternative approach to the assessment of both muscle mass and muscle quality. While  
119 there is some evidence to support the use of diagnostic ultrasound to estimate LBM (13,14,16), this  
120 method of body composition analysis is not widely used for sarcopenia screening and staging.  
121 Currently, diagnostic ultrasound is not identified as an accepted method to determine LBM by the  
122 major international sarcopenia consensus groups (23–25). Therefore, the objectives of this pilot study  
123 are to examine if a rapid assessment method via mobile diagnostic ultrasound augments well-known  
124 determinants of LBM to aid sarcopenia staging, and if a sonographic measure of muscle quality is  
125 associated with muscle performance.



126  
127  
128

## 129 **Materials and Methods**

### 130 *Participants.*

131 Twenty community-dwelling women were enrolled for participation in the study at the George  
132 Washington University (GW) Exercise Physiology Lab in Washington, DC. The study was approved  
133 by the GW Office of Human Research Institutional Review Board, and registered with  
134 Clinicaltrials.gov (NCT00303446). Signed informed consent was obtained from all study  
135 participants prior to data collection. Inclusion criteria for study enrolment included being an  
136 ambulatory female adult between the ages of 18 and 75 years of age. This sample of convenience  
137 was stratified to include an equal number of people above and below the age of 55. Federal agencies  
138 have identified the age range of 55 to 65 as a benchmark period to observe the emergence of age-  
139 related health problems within U.S. populations (26). Absolute contraindications included pregnancy,  
140 medical conditions that result in edema, and musculoskeletal or neurological disorders that are  
141 associated with muscle atrophy. Relative contraindications were body size dimensions that would  
142 preclude appropriate use of the DXA scanner. Participant demographics are summarized in Table 1.

143

144

### 145 *Procedures.*

146

147 The primary estimate of LBM was obtained via whole body DXA imaging using a GE Lunar iDXA  
148 machine (GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC, Madison, WI, USA).  
149 A single trained DXA technician administered all DXA examinations using the GE Encore v15 SP2  
150 software package for the LBM data acquisition and analysis. The body composition data collected  
151 during the DXA examinations included estimates of absolute and percentage of total LBM, aLM/ht<sup>2</sup>,  
152 and body fat percentage (BF%). The aLM values were calculated as the sum of LBM in the arms and  
153 legs and scaled to height (aLM/ht<sup>2</sup>). Participant preparation and positioning for DXA was according  
154 to the GE DXA machine manufacturer's manual and the GW Exercise Science Laboratory testing  
155 procedures. DXA scans were obtained on the same day as the diagnostic ultrasound examination.  
156 Similar DXA imaging equipment and examination procedures (27) have yielded reliable  
157 measurement results (ICC = 0.97,  $p < .0001$ ; CV = 5.5% for LBM) (28).

158

159 Sonographic estimates of LBM (aggregate muscle thickness, cm) and myosteatosis (echogenicity  
160 levels expressed as grayscale values, 0-255) were obtained by a single trained and certified  
161 sonographer. Image capture was completed using a portable, diagnostic ultrasound device (SonoSite  
162 M-Turbo 1.1.2; SonoSite, Inc., Bothell, WA, USA) with a 13.6 MHz linear array transducer and B-  
163 mode scanning. Ample amounts of water-soluble transmission gel was applied to the transducer in  
164 order to maintain adequate acoustic contact with the skin surface. Minimal examiner pressure was  
165 exerted during the scanning to attain sufficient image resolution while incurring nominal tissue  
166 deformation. The unilateral (15) axial and appendicular sites included the midpoint of the upper  
167 trapezius, upper pectoralis major, lateral deltoid, proximal forearm (mobile wad compartment), and  
168 rectus femoris (dominant side only) as identified via palpation of surface anatomy and confirmed via  
169 real-time sonography. Imaging was completed while the participants were seated with their feet on  
170 the floor and upper arms relaxed and aligned with the trunk. Their elbows, hips, and knees were  
171 positioned with approximately 90° of flexion. These anterior locations were determined by

172 considering accessibility during their future use with non-ambulatory patients, the targeted region of  
173 interest (ROI) relative to the ultrasound imaging window and depth, previous use in other  
174 investigations, or clear anatomical landmarks that aid the imaging process (29,30). All longitudinal  
175 view images were obtained and measured 3 times using digital calipers within the fascial borders of  
176 the muscle at the time of image capture, and the values were averaged prior to analysis. Acceptable  
177 intra-rater reliability (30,31) for diagnostic ultrasound assessment has been found for tests involving  
178 the thickness and cross-sectional area of the rectus femoris ( $ICC_{3,2} = 0.72-0.99$ ,  $p < 0.05$ ;  $CV = 3.5\%$   
179 to  $6.7\%$ ) and similar morphology measures for the trapezius have also been reported as reliable  
180 ( $ICC_{3,3} = 0.88-0.96$ ,  $p < 0.05$ ). Also, the investigators involved in this study demonstrated a CV of  
181  $1.6\%$  to  $2.9\%$  for material thickness measures across 6 raters using a calibration phantom (32) and  
182 high interrater reliability ( $ICC_{2,k} = .992 - .996$ ,  $p < .001$ ) for the assessment of echogenicity at the  
183 rectus femoris via grayscale histogram analysis (33).

184  
185 Additional assessments included hand grip dynamometry (Jamar, Lafayette Instruments, Lafayette,  
186 IN) using the mean value of 3 trials under standardized conditions (34). Grip strength is a frequently  
187 used impairment measure in studies concerning general muscle function and older adults (35), and  
188 the reliability of the Jamar dynamometer is suitable for clinical research settings ( $ICCs = 0.97-0.98$ ,  $p$   
189  $< 0.01$ ). Basic anthropometric measures such as height (cm) with a stadiometer and body mass (kg)  
190 with a balance scale were completed prior to body composition testing, and participants provided  
191 general information concerning racial/ethnic group identify, limb dominance (based on the stated  
192 preference for handwriting and kicking a ball), past medical history, alcohol intake (The Alcohol Use  
193 Disorders Identification Test, AUDIT-C) (36), health-related quality of life (The Health Assessment  
194 Questionnaire, HAQ) (37), and smoking behavior.

195  
196  
197 *Data Analysis.*

198  
199 Descriptive statistics are used to depict participant characteristics and the outcome measures, and  
200 data are expressed as means and standard deviations. The major outcomes in this study have normal  
201 data and variance distributions based on the Shapiro-Wilk and Levene's test, respectively, except for  
202 the ultrasound echogenicity grayscale values and BMI. These data are shown as median values with  
203 the interquartile range (IQR) and further analyses are completed using non-parametric statistics or  
204  $\log_{10}(x)$  data transformations (38). Inferential statistics include an analysis of relationships among  
205 the measures of body composition and muscle performance. Pearson product-moment correlation  
206 coefficients (PMCC,  $r$ ), partial correlations ( $r_{xy \cdot z}$ ), and Spearman's correlation coefficients  
207 (Spearman's rho,  $\rho$ ) are used to assess the association between variables, and the strength of the  
208 association among the variables is based on Munro's criteria (39). Independent t-tests and Mann  
209 Whitney U tests are used to determine the difference among the variables based on the categorization  
210 of participants in "Normal LBM" and "Low LBM" subgroups. The LBM criterion is based on the  
211 Class I designation for sarcopenia in women ( $5.76-6.75 \text{ kg/m}^2$ ) by Janssen and colleagues (5).

212  
213 Nested linear multiple regression with *a priori* variable selection is used to assess the presumed  
214 association of LBM with measures of body size, ultrasound morphometry measures of muscle  
215 thickness, and age. Significant improvements in the regression models are based of the change in  $F$   
216 values derived from an analysis of variance (ANOVA). Stepwise multiple linear regression analysis  
217 is used to determine the association of muscle strength with LBM, echogenicity, body size, body fat  
218 (BF), and age. Data residuals are assessed for homoscedasticity and Cook's Distance scores are  
219 assessed to ensure that individual data are not disproportionately influencing the regression equation.  
220 Multicollinearity of the covariates is initially assessed through the review of a correlation matrix, and

221 then calculating the variance inflation factors (VIF), tolerance statistics (1/VIF), and the covariate  
 222 dependency associated with each eigenvalue following the regression analysis (40). VIF values  $\geq 10$   
 223 denote multicollinearity, and an average VIF  $> 1$  or  $1/\text{VIF} < .1$  prompts the review of the variance  
 224 proportions associated with the eigenvalue dimensions for the final regression model. Covariate  
 225 dependency observed within any eigenvalue dimension will also serve to confirm the presence of  
 226 multicollinearity.

227

228 The construct of “strength” is represented by the averaged peak grip force values scaled to body  
 229 weight given the well-known influence of body size on the expression on unadjusted strength values  
 230 (kg of peak force/kg of body weight) (41,42). Echogenicity measures are expressed as median  
 231 grayscale values (a unitless 0-255 scale, with higher values indicating more hyperechoic material) via  
 232 image analysis using Adobe Photoshop® version 6 (Adobe Systems, Mountain View, CA, USA)  
 233 (33). Total sample data and/or subgroup data were subject to analysis based on the nature of a given  
 234 research question associated with the study objectives. Statistical analyses were performed using  
 235 SPSS statistical software version 10.0 for Windows (SPSS Inc., Chicago, IL, USA). The  $\alpha$  level was  
 236 set at .05, and two-tailed  $p$  values  $< .05$  were considered significant for all inferential statistics.

237

238

## 239 Results

240

### 241 *Participant characteristics*

242

243 Our sample includes 20 female participants with a mean age of  $43.4 \pm 20.9$  years with a median BMI  
 244 of 23.8 (IQR, 8.5) and a mean aLM/ht<sup>2</sup> of  $6.96 \pm 1.22$ . Ratings of health-related quality of life via the  
 245 HAQ were similar to those reported in population-based studies, no excessive alcohol intake was  
 246 detected using the Audit-C questionnaire, and no participant reported a history of smoking (36,37).  
 247 The assignment of participants to Normal LBM and Low LBM subgroups reveals that the Normal  
 248 LBM subgroup exhibit higher BMI values ( $p = .001$ ) and echogenicity levels ( $p = .003$ ), but lower  
 249 scaled grip strength values ( $p = .017$ ) in comparison to the Low LBM group. Ultrasound estimates of  
 250 LBM via aggregate total muscle thickness values significantly discriminate between the Normal  
 251 LBM and the Low LBM subgroups ( $p = .006$ ). All participant characteristics and demographic  
 252 information are provided in Table 1.

253

254

### 255 *Using ultrasound muscle characteristics to improve predictors of lean body mass*

256

257 While ultrasound morphometry measures are independently associated with LBM ( $.64, p = .002$ ), a  
 258 multiple regression model using the aggregate ultrasound muscle thickness measures with estimates  
 259 of body size and participant age provides the strongest association with DXA LBM values. The  
 260 iterations of the linear regression model show that BMI alone is a predictor of aLM/ht<sup>2</sup> (adjusted  $R^2$   
 261 of  $.61, p < .001$ , using  $\log_{10}(x)$  values for BMI). However, the model is significantly improved ( $\Delta R^2$   
 262 =  $.13, F(2, 17) = 32.5, p < .004$ ) with the addition of aggregate ultrasound muscle thickness  
 263 (adjusted  $R^2$  of  $.77, p < .001$ ) and age ( $\Delta R^2 = .08, F(3, 16) = 35.4, p < .007$ ) as predictor variables.  
 264 The *a priori* regression model of BMI, ultrasound muscle thickness, and age yields an adjusted  $R^2$  of  
 265  $.85 (p < .001; \text{Table } 2)$ . The partial correlations within this model show the strength of association  
 266 between BMI and aLM/ht<sup>2</sup> ( $r_{xy \cdot z} = .88$ ). Contributing predictor variables, ultrasound muscle thickness  
 267 and age, exhibit a similar magnitude of association with aLM/ht<sup>2</sup> ( $r_{xy \cdot z} = .58$  and  $-.61$ , respectively).  
 268 In examining the potential presence of multicollinearity within the regression model, the 1/VIF was

269 .66-.76 and the VIF was 1.3-1.5. The variance proportions associated with the eigenvalue dimensions  
 270 do not reveal covariate dependency. The highest regression coefficient variances observed across all  
 271 eigenvalue dimensions are for BMI (.97) and age (.16) within eigenvalue dimension 4 of the final  
 272 regression model.

273  
 274  
 275  
 276

277 *Muscle quality estimates, body composition estimates, and peak force generation*

278

279 Estimates of muscle quality, proportion of total body fat, and age, but not LBM, are significantly  
 280 associated with scaled peak force production. Peak force generation was represented by dominant  
 281 limb grip dynamometry scaled to body weight in our sample (differences between dominant and non-  
 282 dominant strength values were not significant; data not shown). Participant age and ultrasound  
 283 echogenicity measured at the dominant limb rectus femoris are moderately associated with strength ( $r$   
 284 = -.69,  $p = .001$ , and  $\rho = -.67$ ,  $p = .001$ , respectively). Considering the body composition measures  
 285 obtained using DXA, percentage body fat (BF%) is moderately associated with scaled peak force ( $r$   
 286 = -.63,  $p = .003$ ), but LBM as estimated with aLM/ht<sup>2</sup> is not ( $r = -.34$ ,  $p = .14$ ).

287

288 The bivariate linear regression model with age as a predictor of scaled peak force yields an adjusted  
 289  $R^2$  of .39,  $p = .002$ . The addition of ultrasound echogenicity, as quantified with grayscale histogram  
 290 analysis (using  $\log_{10}(x)$  grayscale values), significantly improves the model ( $\Delta R^2 = .16$ ,  $F(2, 18) =$   
 291  $11.8$ ,  $p = .017$ ). The multiple regression model with age and echogenicity as predictor variables  
 292 accounts for approximately 53% of the variance in the scaled peak force values ( $p = .001$ ; Table 3).  
 293 The partial correlations within this model suggest that echogenicity may have a greater magnitude of  
 294 association with scaled peak force ( $r_{xy \cdot z} = -.52$ ) in comparison with participant age ( $r_{xy \cdot z} = -.38$ ). The  
 295 addition of other predictor variables associated with body size and body composition, such as BMI  
 296 and BF%, only serve to diminish the integrity of regression model ( $F$  value decreases from 13.3 to <  
 297 7.9 without a resultant increase in the adjusted  $R^2$  value). Regression model diagnostics are negative  
 298 for multicollinearity based on a  $1/\text{VIF}$  of .62, a VIF of 1.6, and an absence of covariate dependency  
 299 within the eigenvalue dimensions. Figure 1 depicts the scatterplot for scaled peak force and  
 300 echogenicity expressed as grayscale values ( $\log_{10}(x)$ ).

301

302

303 **Discussion**

304

305 Age-related muscle dysfunction may be marked by both a loss of LBM and diminished muscle tissue  
 306 composition. While the assessment of muscle quality is not yet included in the staging algorithm for  
 307 sarcopenia (24), intrinsic muscle characteristics beyond size are known to affect strength and  
 308 contribute to mobility limitations (43,44). Mobile, diagnostic ultrasound has been proposed as a  
 309 method to obtain estimates of muscle mass and muscle quality, while circumventing the constraints  
 310 of traditional imaging modalities related to access, cost, and radiation exposure (45,46). The primary  
 311 objectives of this study are to examine if diagnostic ultrasound muscle characteristics help to improve  
 312 well-known determinants of LBM, and if the measurement of muscle quality via ultrasound  
 313 echogenicity is associated with muscle performance.

314

315

316 *Diagnostic ultrasound and LBM estimates: improving on available clinical information*

317 Standard clinical information such as age and BMI are significantly associated with LBM, but fall  
 318 short of full consideration as proxy measures. Our data is consistent with the findings of a larger  
 319 study conducted by Iannuzzi-Sucich and colleagues (12) who determined that BMI independently  
 320 accounts for approximately 50% of the variance in aLM/ht<sup>2</sup>. Also, Goodman and associates (47) have  
 321 used logistic regression models with factors for BMI and age to identify older men and women with  
 322 low aLM/ht<sup>2</sup> based on data culled from the National Health and Nutrition Examination Surveys  
 323 database (1999 to 2004) and comparisons with a young cohort reference group. In this study, we  
 324 have used a conceptual aLM/ht<sup>2</sup> prediction model based on BMI, age, and a direct measure of muscle  
 325 morphometry via diagnostic ultrasound. The general use of BMI remains problematic (11,48)  
 326 concerning the misclassification of very fit individuals as “overweight”, its potential overestimate of  
 327 obesity rates in African Americans, and the wide range of BF% levels attributed to people with a  
 328 BMI range between 20 and 30. However, the value of retaining BMI within the proposed aLM/ht<sup>2</sup>  
 329 prediction model is its significant association with LBM in many patient populations, and its  
 330 representation of body size which serves to provide a scaling factor for the aggregate muscle  
 331 thickness values obtained via sonography. An additional potential benefit of using diagnostic  
 332 ultrasound data for an aLM/ht<sup>2</sup> prediction model, and during the general sarcopenia assessment  
 333 process, is the viable opportunity to integrate estimates muscle quality into the sarcopenia staging  
 334 algorithm. The development of valid predictive models of LBM still remains an important goal  
 335 concerning the staging of sarcopenia and the monitoring of other chronic conditions. Indeed, low  
 336 LBM and muscle performance constitute health concerns that may act as independent mortality risk  
 337 factors (49). Nevertheless, muscle quality may surpass muscle mass as a contributor to age-related  
 338 decreases in muscle strength and power, and negatively impact functional independence (50–52).  
 339 Additional investigation will be needed to refine the operational definitions of muscle quality and to  
 340 understand how to best incorporate this muscle characteristic into the sarcopenia syndrome  
 341 framework.

342  
 343

344 *Muscle quality should not be ignored as a component of the sarcopenia syndrome*

345

346 Older adults categorized as mildly overweight based on their BMI are less likely to develop  
 347 sarcopenia using LBM as the criterion (53). Individuals that are mildly overweight may exhibit a  
 348 protective effect against muscle loss and maintain functional independence as they age despite a  
 349 concomitant increased risk for cardiovascular disease and other systemic disorders (54). Indeed,  
 350 BMI significantly ( $p = .001$ ) discriminates between participants in this study assigned to the Normal  
 351 LBM subgroup ( $> 6.75 \text{ kg/m}^2$ ) and Low LBM subgroup ( $5.76\text{-}6.75 \text{ kg/m}^2$ ). The Normal LBM  
 352 subgroup has a mean LBM value of  $7.92 \pm .88 \text{ kg/m}^2$  and a BMI of 28.8 (IQR, 9.4), whereas the Low  
 353 LBM subgroup has a mean LBM value of  $6.00 \pm .55 \text{ kg/m}^2$  and a BMI of 21.5 (IQR, 3.1). Therefore,  
 354 the Normal LBM subgroup appears to reflect previously published findings concerning the LBM  
 355 sparing effect of higher relative body weight levels. Nevertheless, the Normal LBM subgroup also  
 356 exhibits *lower* scaled peak force values and *higher* echogenicity values in comparison to the Low  
 357 LBM subgroup (Figure 2). The women assigned to the Low LBM subgroup are classified as having  
 358 “healthy body weight” per the BMI designation, and they also have a lower proportion of total body  
 359 fat, higher relative strength levels based on grip dynamometry, and better estimates of muscle quality  
 360 (i.e., 35% lower echogenicity levels in comparison to the Normal LBM subgroup; Table 1).

361

362 While forms of muscle quality are not part of the current sarcopenia staging algorithm, the concept  
 363 remains useful for examining contributing factors to muscle performance. Muscle quality in  
 364 sarcopenia studies is sometimes expressed as peak force generated from a single testing maneuver

365 scaled to regional DXA estimates of muscle mass (55,56). Scaling net muscle force production  
366 relative to muscle mass or body mass allows one to compare strength within a heterogeneous sample  
367 regarding body stature, and account for the effect of body size on strength-function relationships  
368 (41). Recently, the investigators involved in the Foundation for the National Institutes of Health  
369 (FNIH) Sarcopenia Project examined grip strength cut points related to mobility limitations.  
370 Although they opted to affirm the use of absolute strength values in a manner similar to other  
371 international sarcopenia consensus groups (24), they did note the modest improvements in the model  
372 equations for women within their pooled cross-sectional sample when using grip strength scaled to  
373 BMI (57). While, the aforementioned scaling approach has been termed “specific force” in previous  
374 studies (55,56), there may be important distinctions between scaling factors and specific force that  
375 merit consideration. Specific force has traditionally been determined by calculating muscle strength  
376 relative to whole muscle cross-sectional area (CSA), and is usually depicted as a simple linear  
377 relationship that may have some validity in unipennate muscles with fairly uniform architecture.  
378 However, the assumptions of specific force derived from CSA estimates do not apply to the vast  
379 majority of muscle groups. Consequently, specific force is often formally expressed as the quotient  
380 of muscle force and physiologic cross-sectional area (PCSA), which incorporates aspects of muscle  
381 architecture such as muscle fiber length and pennation angle (58–60). Additional intrinsic factors  
382 such as moment arm length, muscle fiber type, muscle action mode, bioenergetics, excitation-  
383 contraction coupling, and muscle tissue composition act to influence specific force. Furthermore,  
384 factors extrinsic to the muscle – but inextricably linked with net force production – include sufficient  
385 cortical excitability, the integrity of pyramidal neurons, the synchrony and rate coding of alpha motor  
386 neurons, and the impact of age-related motor neuron loss (61,62). Given the varied physiological  
387 factors that govern muscle performance, these insights imply that the use of specific force to  
388 represent muscle quality has important constraints. Rather, the calculation of specific force could be  
389 considered as one of many impairment-level outcomes that are responsive to changes in muscle  
390 quality and other facets of the neuromuscular milieu.

391  
392 In this report, muscle quality is operationally defined as muscle tissue echogenicity which serves as a  
393 proxy measure for tissue composition (17,22). The rationale for considering diminished tissue  
394 composition as a major indicator of age-related muscle changes is partially validated through the  
395 significant inverse relationship between scaled peak force and echogenicity observed in our data  
396 (Figure 1). Given that LBM did not have a meaningful association with scaled peak force, and that  
397 age and echogenicity accounted for approximately 50% of the variance in strength levels, our pilot  
398 data allows for the consideration of additional intrinsic and extrinsic muscle factors contributing to  
399 the observed strength levels within the sample.

400

401

#### 402 *Study implications and limitations*

403

404 The findings from this study suggest that diagnostic ultrasound may be used in combination with  
405 readily available clinical information to estimate LBM. Although the models derived from the data  
406 must be considered exploratory given the limited sample size, the *a priori* explanatory variables lend  
407 strength to our general approach (40). While the coefficients used in the regression equations may  
408 change substantially during validation with a larger sample and with the inclusion of male subjects,  
409 we hypothesize that the explanatory variables of BMI, ultrasound muscle thickness, and age will  
410 retain their value within the model. Use of the Class I designation for sarcopenia in women (i.e.,  
411 5.76-6.75 kg/m<sup>2</sup>) is appropriate for our participants given their relatively high level of physical  
412 functioning, and serves as an approach to discriminate meaningful body composition differences  
413 within the sample (5). More stringent LBM criterion values, such as those ascribed to the Class II

414 sarcopenia designation or the FNIH sarcopenia staging algorithm, yield lower prevalence values (63)  
415 and may be more suitable for population-based studies with a sufficient representation of participants  
416 with a high degree of physical impairment.

417  
418 Muscle echogenicity was significantly associated with peak muscle force in our sample. It is  
419 important to note that the sonographic morphology measures used for the proxy muscle tissue  
420 composition estimates were obtained at the rectus femoris. The selection of the rectus femoris for  
421 echogenicity assessment is influenced by its favorable architecture and uniform geometry in the  
422 longitudinal orientation during scanning. Previous observations confirm that echogenicity of skeletal  
423 muscles vary with their location within the body, with muscle groups within the lower compartment  
424 of the leg having higher echogenicity in comparison to selected upper body muscle groups (45,64).  
425 We hypothesized that while skeletal muscles have differing levels of echogenicity based on their  
426 location and metabolic profile, age-related changes in muscle tissue composition would be systemic  
427 and result in a broad increase in echogenicity across muscle groups. This proposed phenomenon is  
428 partially supported by our findings in this study concerning the observed significant relationship  
429 between echogenicity at the rectus femoris with peak grip force. Just as grip strength has been used  
430 as a global measure that may be significantly associated with knee extension strength and general  
431 physical performance in older adults (65,66), echogenicity at the knee extensors may be a general  
432 indicator of muscle quality that is inversely related with grip strength and general measures of muscle  
433 performance. For example, our preliminary data (67) involving a group of older men suggest that  
434 echogenicity levels at the rectus femoris are significantly related to scaled peak grip strength, walking  
435 speed, and the timed sit-to-stand test ( $r = -.30$  to  $-.71$ ,  $p < .05$ ). Further study will be needed to better  
436 understand the effect of sexual dimorphism on the age-related changes in muscle tissue composition  
437 as assessed with sonographic proxy measures. Also, larger follow up studies will be needed to  
438 explore the risk of incident mobility limitations and physical disability based on muscle quality  
439 estimates as described in this work.

440  
441 Investigators have also reported findings that suggest that changes in muscle tissue composition may  
442 differentially affect people of African descent (7,68,69). Both advancing age and BF% may be  
443 associated with adverse changes in muscle tissue composition. However, high levels of intramuscular  
444 adipose tissue in African Americans may be observed in those classified as having “healthy body  
445 weight” based on their BMI, and be independent of central adiposity (69). Individuals with this type  
446 of muscle tissue composition profile may have associated health problems that include metabolic  
447 dysfunction or diminished muscle performance, and yet not meet the staging criteria for sarcopenia.  
448 Indeed, there is some evidence to suggest that African Americans may have a lower prevalence of  
449 sarcopenia in comparison to non-Hispanic Whites (70). We do not have a sufficient sample size to  
450 subject our racial/ethnic group data to inferential analysis. However, we observed that none of our  
451 African American or Hispanic participants are in the Low LBM subgroup (Table 1). These 6  
452 participants are in the Normal LBM subgroup which is characterized by higher mean BMI and  
453 median echogenicity values in comparison to the Low LBM subgroup. Other limitations in this work  
454 related to the modest sample size include the departures from normality related to the distribution of  
455 the BMI and grayscale values which was addressed via data transformation. Also, the constraints of  
456 standard diagnostic ultrasound imaging did not allow for us to obtain the additional measures of CSA  
457 or PSCA at the mid-thigh. While grip dynamometry is the recommended means of strength testing  
458 according to the leading sarcopenia consensus organizations (10,23,25), the study findings may have  
459 been enhanced by obtaining estimates of lower extremity muscle performance.

460

461 It remains to be seen if screening for age-related changes in muscle quality may be effectively used to  
 462 modify the risk of developing chronic disease and disabling conditions related to musculoskeletal  
 463 health. In addition, the benefits of diagnostic ultrasound to characterize skeletal muscle have to be  
 464 considered with the shortcomings of the imaging modality related to equipment access, examiner  
 465 training, limited normative datasets, and the inter-machine equivalence of echogenicity values (46).  
 466

467

468 **Conclusions**

469

470 Diagnostic ultrasound may provide a clinically viable means to assess both muscle mass and muscle  
 471 quality. Our study findings indicate that a conceptual aLM/ht<sup>2</sup> prediction model based on BMI, age,  
 472 and a direct measure of muscle morphometry via diagnostic ultrasound, accounts for 85% of the  
 473 variance in DXA LBM values for our sample. Moreover, our data suggest that age and muscle  
 474 echogenicity, are significantly associated with scaled peak force production in the women that  
 475 participated in our study. In contrast, DXA LBM is not significantly associated with scaled peak  
 476 force generation in our participants. The higher total BF% of the Normal LBM subgroup may have  
 477 conferred a protective effect against low muscle mass, but not myosteatosis. The women in the  
 478 Normal LBM subgroup exhibit higher BMI values and echogenicity levels, but lower scaled peak  
 479 force values in comparison to the Low LBM group. Follow up studies should include validation of  
 480 the aLM/ht<sup>2</sup> prediction model, and the integration of ultrasound estimates of muscle quality into the  
 481 sarcopenia staging algorithm.

482

483

484 **Acknowledgments**

485 Funding for this project was provided by the National Center for Advancing Translational Sciences,  
 486 National Institutes of Health (NIH), through the Clinical and Translational Science Awards Program  
 487 (CTSA grant: CTSI-CN #UL1TR000075), with additional support from the VA Office of Academic  
 488 Affiliations (OAA; 38 U.S.C 7406) and the VA Office of Research and Development.

489

490 Any opinions or recommendations expressed in this publication are those of the authors and do not  
 491 necessarily reflect the view of the U.S. Department of Veterans Affairs or the U.S. Department of  
 492 Health and Human Services.

493

494



495

496 **References**

- 497 1. Kamel HK. Sarcopenia and aging. *Nutr Rev* (2003) **61**:157–67.
- 498 2. Hughes VA, Frontera WR, Wood M, Evans WJ, Dallal GE, Roubenoff R, Singh MAF.  
499 Longitudinal muscle strength changes in older adults: influence of muscle mass, physical  
500 activity, and health. *J Gerontol A Biol Sci Med Sci* (2001) **56**:B209–B217.  
501 doi:10.1093/gerona/56.5.B209
- 502 3. Frontera WR, Reid KF, Phillips EM, Krivickas LS, Hughes VA, Roubenoff R, Fielding RA.  
503 Muscle fiber size and function in elderly humans: a longitudinal study. *J Appl Physiol* (2008)  
504 **105**:637–642. doi:10.1152/jappphysiol.90332.2008
- 505 4. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and  
506 the impact of advancing age on human skeletal muscle size and strength; a quantitative review.  
507 *Front Physiol* (2012) **3**:260. doi:10.3389/fphys.2012.00260
- 508 5. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints  
509 associated with elevated physical disability risk in older men and women. *Am J Epidemiol* (2004)  
510 **159**:413–421.
- 511 6. Vandervoort AA. Aging of the human neuromuscular system. *Muscle Nerve* (2002) **25**:17–25.
- 512 7. Song M-Y, Ruts E, Kim J, Janumala I, Heymsfield S, Gallagher D. Sarcopenia and increased  
513 adipose tissue infiltration of muscle in elderly African American women. *Am J Clin Nutr* (2004)  
514 **79**:874–880.
- 515 8. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G,  
516 Andrieu S, Bauer J, Breuille D, et al. Sarcopenia: an undiagnosed condition in older adults.  
517 Current consensus definition: prevalence, etiology, and consequences. International working  
518 group on sarcopenia. *J Am Med Dir Assoc* (2011) **12**:249–256. doi:10.1016/j.jamda.2011.01.003
- 519 9. Malmstrom TK, Miller DK, Herning MM, Morley JE. Low appendicular skeletal muscle mass  
520 (ASM) with limited mobility and poor health outcomes in middle-aged African Americans. *J*  
521 *Cachexia Sarcopenia Muscle* (2013) doi:10.1007/s13539-013-0106-x
- 522 10. Cruz-Jentoft AJ, Morley JE eds. *Sarcopenia*. Chichester, West Sussex: John Wiley & Sons  
523 (2012).
- 524 11. Harris-Love MO, Adams B, Hernandez HJ, DiPietro L, Blackman MR. Disparities in the  
525 consequences of sarcopenia: implications for African American Veterans. *Front Physiol* (2014)  
526 **5**: doi:10.3389/fphys.2014.00250
- 527 12. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of  
528 skeletal muscle mass in healthy, older men and women. *J Gerontol A Biol Sci Med Sci* (2002)  
529 **57**:M772–777.

- 530 13. Pineau J-C, Guihard-Costa A-M, Bocquet M. Validation of ultrasound techniques applied to  
 531 body fat measurement. A comparison between ultrasound techniques, air displacement  
 532 plethysmography and bioelectrical impedance vs. dual-energy X-ray absorptiometry. *Ann Nutr*  
 533 *Metab* (2007) **51**:421–427. doi:10.1159/000111161
- 534 14. Utter AC, Hager ME. Evaluation of ultrasound in assessing body composition of high school  
 535 wrestlers. *Med Sci Sports Exerc* (2008) **40**:943–949. doi:10.1249/MSS.0b013e318163f29e
- 536 15. Abe T, Kondo M, Kawakami Y, Fukunaga T. Prediction equations for body composition of  
 537 Japanese adults by B-mode ultrasound. *Am J Hum Biol* (1994) **6**:161–170.  
 538 doi:10.1002/ajhb.1310060204
- 539 16. Sanada K, Kearns CF, Midorikawa T, Abe T. Prediction and validation of total and regional  
 540 skeletal muscle mass by ultrasound in Japanese adults. *Eur J Appl Physiol* (2006) **96**:24–31.  
 541 doi:10.1007/s00421-005-0061-0
- 542 17. Sipilä S, Suominen H. Muscle ultrasonography and computed tomography in elderly trained and  
 543 untrained women. *Muscle Nerve* (1993) **16**:294–300. doi:10.1002/mus.880160309
- 544 18. Cady EB, Gardener JE. “Tissue Characterization of Normal and Dystrophic Muscle Using  
 545 Broad-Band Backscattered R.F. Data,” in *Ultrasound Interactions in Biology and Medicine*, eds.  
 546 R. Millner, E. Rosenfeld, U. Cobet (Boston, MA: Springer US), 77–84. Available at:  
 547 [http://www.springerlink.com/index/10.1007/978-1-4684-8384-0\\_10](http://www.springerlink.com/index/10.1007/978-1-4684-8384-0_10) [Accessed August 25, 2013]
- 548 19. Berger G, Laugier P, Fink M, Perrin J. Optimal precision in ultrasound attenuation estimation  
 549 and application to the detection of Duchenne muscular dystrophy carriers. *Ultrason Imaging*  
 550 (1987) **9**:1–17.
- 551 20. Schapira G, Laugier P, Rochette J, Berger G, Katz P, Perrin J. Detection of Duchenne muscular  
 552 dystrophy carriers: quantitative echography and creatine kinasemia. *Hum Genet* (1987) **75**:19–23.
- 553 21. Hughes MS, Marsh JN, Wallace KD, Donahue TA, Connolly AM, Lanza GM, Wickline SA.  
 554 Sensitive ultrasonic detection of dystrophic skeletal muscle in patients with Duchenne muscular  
 555 dystrophy using an entropy-based signal receiver. *Ultrasound Med Biol* (2007) **33**:1236–1243.  
 556 doi:10.1016/j.ultrasmedbio.2007.02.007
- 557 22. Reimers K, Reimers CD, Wagner S, Paetzke I, Pongratz DE. Skeletal muscle sonography: a  
 558 correlative study of echogenicity and morphology. *J Ultrasound Med* (1993) **12**:73–77.
- 559 23. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel J-P,  
 560 Rolland Y, Schneider SM, et al. Sarcopenia: European consensus on definition and diagnosis:  
 561 Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* (2010)  
 562 **39**:412–423. doi:10.1093/ageing/afq034
- 563 24. Lee W-J, Liu L-K, Peng L-N, Lin M-H, Chen L-K, ILAS Research Group. Comparisons of  
 564 sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan  
 565 longitudinal aging study. *J Am Med Dir Assoc* (2013) **14**:528.e1–7.  
 566 doi:10.1016/j.jamda.2013.03.019

- 567 25. Dam T-T, Peters KW, Fragala M, Cawthon PM, Harris TB, McLean R, Shardell M, Alley DE,  
568 Kenny A, Ferrucci L, et al. An evidence-based comparison of operational criteria for the presence  
569 of sarcopenia. *J Gerontol A Biol Sci Med Sci* (2014) **69**:584–590. doi:10.1093/gerona/glu013
- 570 26. Schoenborn CA, Heyman KM. Health characteristics of adults aged 55 years and over: United  
571 States, 2004-2007. *Natl Health Stat Rep* (2009)1–31.
- 572 27. Hull H, He Q, Thornton J, Javed F, Wang J, Pierson RN, Gallagher D. iDXA, Prodigy, and  
573 DPXL dual-energy X-ray absorptiometry whole-body scans: a cross-calibration study. *J Clinical*  
574 *Densitom* (2009) **12**:95–102. doi:10.1016/j.jocd.2008.09.004
- 575 28. Aasen G, Fagertun H, Halse J. Body composition analysis by dual X-ray absorptiometry: in vivo  
576 and in vitro comparison of three different fan-beam instruments. *Scand J Clin Lab Invest* (2006)  
577 **66**:659–666. doi:10.1080/00365510600898214
- 578 29. Ismail C, Hernandez HJ, Adams B, Zabal J, Manning H, Harris-Love MO. Sonographic estimates  
579 of muscle quality: reliability of 3 different methods of grayscale analysis. *J Frailty Aging* (2014)  
580 **3**:75–76.
- 581 30. Bembem MG. Use of diagnostic ultrasound for assessing muscle size. *J Strength Cond Res Natl*  
582 *Strength Cond Assoc* (2002) **16**:103–108. doi:doi:10.1519/00124278-200202000-00016
- 583 31. O’Sullivan C, Bentman S, Bennett K, Stokes M. Rehabilitative ultrasound imaging of the lower  
584 trapezius muscle: technical description and reliability. *J Orthop Sports Phys Ther* (2007) **37**:620–  
585 626. doi:10.2519/jospt.2007.2446
- 586 32. Harris-Love MO, Ismail C, Monfaredi R, Woletz P, Ranniger C, Blackman MR. Quantitative  
587 ultrasound for sarcopenia screening: interrater reliability using a novel method of force feedback.  
588 *The Gerontologist* (2014) **54**:S339. doi:10.13140/RG.2.1.2342.0006
- 589 33. Harris-Love MO, Seamon BA, Teixeira C, Ismail C. Ultrasound estimates of myosteatosis:  
590 reliability and comparison of Adobe Photoshop® and ImageJ for grayscale analysis of muscle  
591 echogenicity. *J Frailty Aging* (2015) **4**:103. doi:10.13140/RG.2.1.3275.3764
- 592 34. Günther CM, Bürger A, Rickert M, Crispin A, Schulz CU. Grip strength in healthy Caucasian  
593 adults: reference values. *J Hand Surg* (2008) **33**:558–565. doi:10.1016/j.jhsa.2008.01.008
- 594 35. Vermeulen J, Neyens JCL, Spreeuwenberg MD, van Rossum E, Hewson DJ, de Witte LP.  
595 Measuring grip strength in older adults: comparing the grip-ball with the Jamar dynamometer. *J*  
596 *Geriatr Phys Ther* (2015) **38**:148–153. doi:10.1519/JPT.0000000000000034
- 597 36. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a  
598 brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res* (2007) **31**:1208–1217.  
599 doi:10.1111/j.1530-0277.2007.00403.x
- 600 37. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical  
601 applications. *Health Qual Life Outcomes* (2003) **1**:20. doi:10.1186/1477-7525-1-20
- 602 38. Portney LG, Watkins MP. *Foundations of Clinical Research: Applications to Practice*. Upper  
603 Saddle River, N.J.: Pearson/Prentice Hall (2009).

- 604 39. Munro BH. *Statistical Methods for Health Care Research*. 4th ed. Philadelphia: Lippincott  
605 (2001).
- 606 40. Field A. *Discovering Statistics Using SPSS*. Los Angeles, CA: Sage (2009).
- 607 41. Jaric S. Role of body size in the relation between muscle strength and movement performance.  
608 *Exerc Sport Sci Rev* (2003) **31**:8–12.
- 609 42. Jaric S. Muscle strength testing - use of normalisation for body size. *Sports Med* (2002) **32**:615–  
610 631.
- 611 43. Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, Stamm E,  
612 Newman AB. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study.  
613 *J Appl Physiol Bethesda Md 1985* (2001) **90**:2157–2165.
- 614 44. Ferrucci L, de Cabo R, Knuth ND, Studenski S. Of Greek heroes, wiggling worms, mighty mice,  
615 and old body builders. *J Gerontol A Biol Sci Med Sci* (2011) **67A**:13–16.  
616 doi:10.1093/gerona/qlr046
- 617 45. Pillen S, van Alfen N. Skeletal muscle ultrasound. *Neurol Res* (2011) **33**:1016–1024.  
618 doi:10.1179/1743132811Y.0000000010
- 619 46. Harris-Love MO, Monfaredi R, Ismail C, Blackman MR, Cleary K. Quantitative ultrasound:  
620 measurement considerations for the assessment of muscular dystrophy and sarcopenia. *Front*  
621 *Aging Neurosci* (2014) **6**:172. doi:10.3389/fnagi.2014.00172
- 622 47. Goodman MJ, Ghate SR, Mavros P, Sen S, Marcus RL, Joy E, Brixner DI. Development of a  
623 practical screening tool to predict low muscle mass using NHANES 1999-2004. *J Cachexia*  
624 *Sarcopenia Muscle* (2013) **4**:187–197. doi:10.1007/s13539-013-0107-9
- 625 48. Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J,  
626 Allison TG, Batsis JA, Sert-Kuniyoshi FH, Lopez-Jimenez F. Accuracy of body mass index in  
627 diagnosing obesity in the adult general population. *Int J Obes* (2008) **32**:959–966.  
628 doi:10.1038/ijo.2008.11
- 629 49. Alexandre TDS, Duarte YADO, Santos JLF, Wong R, Lebrao ML. Sarcopenia according to the  
630 European Working Group on Sarcopenia in Older People (EWGSOP) versus dynapenia as a risk  
631 factor for mortality in the elderly. *J Nutr Health Aging* (2014) **18**:751–756. doi:10.1007/s12603-  
632 014-0450-3
- 633 50. Rech A, Radaelli R, Goltz FR, da Rosa LHT, Schneider CD, Pinto RS. Echo intensity is  
634 negatively associated with functional capacity in older women. *Age Dordr Neth* (2014) **36**:9708.  
635 doi:10.1007/s11357-014-9708-2
- 636 51. Fukumoto Y, Ikezoe T, Yamada Y, Tsukagoshi R, Nakamura M, Mori N, Kimura M, Ichihashi  
637 N. Skeletal muscle quality assessed from echo intensity is associated with muscle strength of  
638 middle-aged and elderly persons. *Eur J Appl Physiol* (2012) **112**:1519–1525.  
639 doi:10.1007/s00421-011-2099-5

- 640 52. Watanabe Y, Yamada Y, Fukumoto, Yokoyama K, Yoshida T, Miyake, Yamagata E, Kimura,  
641 Ishihara. Echo intensity obtained from ultrasonography images reflecting muscle strength in  
642 elderly men. *Clin Interv Aging* (2013) **8**:993–998. doi:10.2147/CIA.S47263
- 643 53. Yu R, Wong M, Leung J, Lee J, Auyeung TW, Woo J. Incidence, reversibility, risk factors and  
644 the protective effect of high body mass index against sarcopenia in community-dwelling older  
645 Chinese adults: Sarcopenia incidence and its risk factors. *Geriatr Gerontol Int* (2014) **14**:15–28.  
646 doi:10.1111/ggi.12220
- 647 54. Cetin DC, Nasr G. Obesity in the elderly: More complicated than you think. *Cleve Clin J Med*  
648 (2014) **81**:51–61. doi:10.3949/ccjm.81a.12165
- 649 55. Cawthon PM, Fox KM, Gandra SR, Delmonico MJ, Chiou C-F, Anthony MS, Sewall A,  
650 Goodpaster B, Satterfield S, Cummings SR, et al. Do muscle mass, muscle density, strength, and  
651 physical function similarly influence risk of hospitalization in older adults? *J Am Geriatr Soc*  
652 (2009) **57**:1411–1419. doi:10.1111/j.1532-5415.2009.02366.x
- 653 56. Hairi NN, Cumming RG, Naganathan V, Handelsman DJ, Le Couteur DG, Creasey H, Waite  
654 LM, Seibel MJ, Sambrook PN. Loss of muscle strength, mass (sarcopenia), and quality (specific  
655 force) and its relationship with functional limitation and physical disability: the Concord Health  
656 and Ageing in Men Project. *J Am Geriatr Soc* (2010) **58**:2055–2062. doi:10.1111/j.1532-  
657 5415.2010.03145.x
- 658 57. Alley DE, Shardell MD, Peters KW, McLean RR, Dam T-TL, Kenny AM, Fragala MS, Harris  
659 TB, Kiel DP, Guralnik JM, et al. Grip strength cutpoints for the identification of clinically  
660 relevant weakness. *J Gerontol A Biol Sci Med Sci* (2014) **69**:559–566.  
661 doi:10.1093/gerona/glu011
- 662 58. Blemker SS, Pinsky PM, Delp SL. A 3D model of muscle reveals the causes of nonuniform  
663 strains in the biceps brachii. *J Biomech* (2005) **38**:657–665. doi:10.1016/j.jbiomech.2004.04.009
- 664 59. Morse CI, Tolfrey K, Thom JM, Vassilopoulos V, Maganaris CN, Narici MV. Gastrocnemius  
665 muscle specific force in boys and men. *J Appl Physiol Bethesda Md 1985* (2008) **104**:469–474.  
666 doi:10.1152/jappphysiol.00697.2007
- 667 60. Krivickas LS, Dorer DJ, Ochala J, Frontera WR. Relationship between force and size in human  
668 single muscle fibres: Muscle fibre size and force. *Exp Physiol* (2011) **96**:539–547.  
669 doi:10.1113/expphysiol.2010.055269
- 670 61. Manini TM, Hong SL, Clark BC. Aging and muscle: a neuron's perspective. *Curr Opin Clin Nutr*  
671 *Metab Care* (2013) **16**:21–26. doi:10.1097/MCO.0b013e32835b5880
- 672 62. Lieber RL. *Skeletal Muscle Structure, Function, and Plasticity: The Physiological Basis of*  
673 *Rehabilitation*. Baltimore: Lippincott Williams & Wilkins (2010).
- 674 63. Clynes MA, Edwards MH, Buehring B, Dennison EM, Binkley N, Cooper C. Definitions of  
675 sarcopenia: associations with previous falls and fracture in a population sample. *Calcif Tissue Int*  
676 (2015) **Epub ahead of print**: doi:10.1007/s00223-015-0044-z

- 677 64. Scholten RR, Pillen S, Verrips A, Zwarts MJ. Quantitative ultrasonography of skeletal muscles in  
678 children: normal values. *Muscle Nerve* (2003) **27**:693–698. doi:10.1002/mus.10384
- 679 65. Cooper C, Fielding R, Visser M, Loon LJ, Rolland Y, Orwoll E, Reid K, Boonen S, Dere W,  
680 Epstein S, et al. Tools in the assessment of sarcopenia. *Calcif Tissue Int* (2013) **93**:201–210.  
681 doi:10.1007/s00223-013-9757-z
- 682 66. Aadahl M, Beyer N, Linneberg A, Thuesen BH, Jørgensen T. Grip strength and lower limb  
683 extension power in 19-72-year-old Danish men and women: the Health2006 study. *BMJ Open*  
684 (2011) **1**:e000192. doi:10.1136/bmjopen-2011-000192
- 685 67. Harris-Love MO, Adams B, Ismail C, Hernandez HJ, McIntosh V, Yang J, Chacko L, Blackman  
686 MR, Garra BS. Ultrasound proxy measures of muscle quality are associated with strength and  
687 functional performance in older men. *J Frailty Aging* (2015) **4**:55–56.  
688 doi:10.13140/RG.2.1.1331.3763
- 689 68. Miljkovic I, Cauley JA, Petit MA, Ensrud KE, Strotmeyer E, Sheu Y, Gordon CL, Goodpaster  
690 BH, Bunker CH, Patrick AL, et al. Greater adipose tissue infiltration in skeletal muscle among  
691 older men of African ancestry. *J Clin Endocrinol Metab* (2009) **94**:2735–2742.  
692 doi:10.1210/jc.2008-2541
- 693 69. Miljkovic-Gacic I, Gordon CL, Goodpaster BH, Bunker CH, Patrick AL, Kuller LH, Wheeler  
694 VW, Evans RW, Zmuda JM. Adipose tissue infiltration in skeletal muscle: age patterns and  
695 association with diabetes among men of African ancestry. *Am J Clin Nutr* (2008) **87**:1590–1595.
- 696 70. Castaneda C, Janssen I. Ethnic comparisons of sarcopenia and obesity in diabetes. *Ethn Dis*  
697 (2005) **15**:664–670.
- 698  
699  
700

701 **Tables**

702

703 **Table 1. Participant characteristics.**

704

705

Subject Characteristics	All subjects (N = 20)	Normal LBM (N = 10)	Low LBM (N = 10)	Sig.
Age (yrs)	43.4 ±20.9	47.9 ±21.3	39.0 ±20.4	.351
BMI <sup>†</sup>	23.8 (8.5)	28.8 (9.4)	21.5 (3.1)	.001
aLM/ht <sup>2</sup> (kg/m <sup>2</sup> )	6.96 ±1.22	7.92 ±.88	6.00 ±.55	<.001
Grip strength (kg <sub>F</sub> /kg <sub>BW</sub> )	.392 ±.089	.345 ±.095	.438 ±.054	.017
Muscle thickness (cm)				
Trapezius	1.20 ±.19	1.27 ±.20	1.12 ±.15	.076
Brachioradialis	1.95 ±.35	2.06 ±.40	1.84 ±.27	.170
Deltoid	2.29 ±.53	2.54 ±.48	2.04 ±.45	.031
Pectoralis major	.78 ±.23	.85 ±.28	.70 ±.15	.163
Rectus femoris	2.17 ±.54	2.34 ±.57	2.00 ±.48	.157
Total muscle thickness (cm)	8.39 ±1.18	9.07 ±1.12	7.70 ±.81	.006
Echogenicity <sup>†‡</sup>	47.50 (23.00)	58.50 (21.00)	38.00 (17.00)	.003
Racial/ethnic group				
Caucasian	9 (45.0%)	3 (30.0%)	6 (60.0%)	-
African American	4 (20.0%)	4 (40.0%)	0 (0.0%)	-
Hispanic	2 (10.0%)	2 (20.0%)	0 (0.0%)	-
Asian	5 (25.0%)	1 (10.0%)	4 (40.0%)	-
HAQ	.45 ±1.10	.50 ±.97	.40 ±1.27	.605
Audit-C <sup>†</sup>	2.0 (2.0)	2.0 (2.0)	2.0 (2.0)	.586

706 LBM, lean body mass; sig, significant; BMI, body mass index; aLM/ht<sup>2</sup>, appendicular lean mass scaled to  
 707 height; F, force; BW, body weight; HAQ, The Health Assessment Questionnaire; Audit-C, The Alcohol Use  
 708 Disorders Identification Test.

709

710 Data expressed as means (± standard deviation); statistically significant differences between the Normal LBM  
 711 subgroup and the Low LBM subgroup were determined using the independent t-test (*p* < .05).

712 <sup>†</sup>Data expressed as medians (interquartile range); statistically significant differences between the Normal  
 713 LBM subgroup and the Low LBM subgroup were determined using the Mann Whitney U test (*p* < .05).

714 <sup>‡</sup>Echogenicity is expressed via grayscale values (0-255).

715  
716  
717  
718  
719  
720  
721

**Table 2. Regression model for aLM/ht<sup>2</sup>.** The linear regression model features lean body mass obtained from dual energy X-ray absorptiometry (DXA) as the dependent variable and the body mass index (BMI) with the aggregate muscle thickness value (US) and age as predictor variables.

Model	<i>r</i>	<i>R</i> <sup>2</sup>	Adjusted <i>R</i> <sup>2</sup>	Std. Error of the Estimate	<i>F</i>	Sig.
1	.81	.66	.61	.731	35.1	<.001
2	.89	.79	.77	.588	32.5	<.001
3	.93	.87	.85	.482	35.4	<.001

722 This *a priori* model utilized a nested linear, multiple regression model with forward entry – Predictors: 1)  
723 log<sub>10</sub>(BMI); 2) log<sub>10</sub> (BMI) + aggregate muscle thickness (via ultrasound, cm); 3) log<sub>10</sub> (BMI) + aggregate muscle  
724 thickness (via ultrasound, cm) + age (years). Dependent Variable: DXA lean body mass (aLM/ht<sup>2</sup>). Model 3:  $\hat{Y}$   
725 = -9.078 + 10.210(log<sub>10</sub> (BMI)) + .302(US) + -.019(age).

726  
727  
728  
729  
730  
731  
732  
733  
734

**Table 3. Regression model for grip strength.** The linear regression model features peak force obtained via grip dynamometry and scaled to body weight as the dependent variable and subject age and ultrasound echogenicity as estimated via grayscale analysis as the predictor variables.

Model	<i>r</i>	<i>R</i> <sup>2</sup>	Adjusted <i>R</i> <sup>2</sup>	Std. Error of the Estimate	<i>F</i>	Sig.
1	.65	.42	.39	.068	13.26	.002
2	.76	.58	.53	.059	11.75	.001

739 This model utilized a nested linear multiple regression with forward variable entry – Predictors: 1) age; 2) age  
740 + log<sub>10</sub> (echogenicity via grayscale). Dependent Variable: grip strength (scaled to body weight; dominant  
741 side). Model 2:  $\hat{Y}$  = .969 - .306(log<sub>10</sub> (echogenicity using grayscale values)) - .001(age).

742




743

744 **Figure Legends**

745 **Figure 1: Bivariate relationship between grip strength and muscle echogenicity.** The scatterplot  
 746 depicts the inverse relationship between grip strength (peak force scaled to body weight) and muscle  
 747 quality as measured via grayscale histogram analysis of the rectus femoris echogenicity.

748




749

750

751 **Figure 2: Diagnostic ultrasound image of the rectus femoris region of interest and the**  
 752 **corresponding grayscale histogram analysis values.** The exemplar images depict the diagnostic  
 753 ultrasound transverse muscle images on the left and the grayscale histograms on the right. The  
 754 bottom ultrasound image shows greater hyperechoic properties in comparison to the top image. The  
 755 comparatively hyperechoic image characteristics of the bottom image correspond to grayscale  
 756 histogram data with a wider distribution and a shift to the right which is associated with larger  
 757 grayscale values. The grayscale value of the bottom image is 66.9 and may indicate a greater  
 758 proportion of intramuscular adipose tissue in comparison to the top image (grayscale value, 35.6).

759



760

Figure 1.JPEG




Figure 2.JPEG

